The primary objective of the study is:
To compare the effect of ATG treatment together with intensified insulin therapy (Group 1) on fasting and glucagon-stimulated C-peptide production with that of intensified insulin therapy only (Group 2) in type 1 diabetes mellitus of recent onset
Secondary objectives are:
To compare the insulin doses between the two groups at 6, 12, 18, and 24 months after diabetes onset
To compare the course of the specific humoral markers of autoimmunity between the groups
To evaluate the significance of in vitro testing of specific T-cell activation by an autoantigen in the long-term follow-up in type 1 diabetes
To assess the safety of ATG treatment in type 1 diabetes

开始日期2000-11-01

申办/合作机构

Institute of Clinical and Experimental Medicine

100 项与 Polyclonal anti-T-cell antibodies(Institute for Clinical and Experimental Medicine) 相关的临床结果

登录后查看更多信息

100 项与 Polyclonal anti-T-cell antibodies(Institute for Clinical and Experimental Medicine) 相关的转化医学

登录后查看更多信息

100 项与 Polyclonal anti-T-cell antibodies(Institute for Clinical and Experimental Medicine) 相关的专利（医药）

登录后查看更多信息

项与 Polyclonal anti-T-cell antibodies(Institute for Clinical and Experimental Medicine) 相关的文献（医药）

2017-08-28·Current Neuropharmacology2区 · 医学

Biological Drugs in Guillain-Barré Syndrome: An Update

2区 · 医学

Review

作者: Pavone, Piero ; Matin, Nassim ; Falsaperla, Raffaele ; Vitaliti, Giovanna ; Romano, Catia ; Motamed-Gorji, Nazgol ; Tabatabaie, Omidreza

BACKGROUNDGuillain-Barré Syndrome (GBS) is currently considered the most common global cause of acute flaccid paralysis. Currently, standard therapy for Guillain-Barré Syndrome includes intravenous immunoglobulin or plasma exchange. Despite medical advances regarding these treatments, many treated patients do not reach full recovery. Therefore several biological agents have attracted the attentions from researchers during the last decades, and various studies have investigated their role in Guillain-Barré Syndrome.OBJECTIVEThe present study aims to address emerging biological approaches to GBS while considering their efficiency and safety in treating the disease.MATERIALS AND METHODSAn extensive electronic literature search was conducted by two researchers from April 2016 to July 2016. Original articles, clinical trials, systematic reviews (with or without meta-analysis) and case reports were selected. Titles and abstracts of papers were screened by reviewers to determine whether they met the eligibility criteria, and full texts of the selected articles were retrieved.RESULTSHerein authors focused on the literature data concerning emerging biological therapeutic agents, namely anti-C5 monoclonal antibody (Eculizumab), anti-C1q monoclonal antibody, anti-T cell monoclonal antibody, anti-CD2 monoclonal antibody, anti L-selectin monoclonal antibody, anti- CD20 monoclonal antibody (Rituximab), anti-CD52 monoclonal antibody (Alemtuzumab) and cytokine targets. By far, none of these agents have been approved for the treatment of GBS by FDA.CONCLUSIONLiterature findings represented in current review herald promising results for using these biological targets. Current review represents a summary of what is already in regards and what progress is required to improve the immunotherapeutic approach of treating GBS via future studies.

2014-01-01·Toxicology Reports

Antibody/doxycycline combined therapy for pulmonary ricinosis: Attenuation of inflammation improves survival of ricin-intoxicated mice

Article

作者: Mazor, Ohad ; Kronman, Chanoch ; Alcalay, Ron ; Aftalion, Moshe ; Gal, Yoav ; Seliger, Nehama ; Sabo, Tamar ; Falach, Reut ; Sapoznikov, Anita

Ricin, a highly toxic plant-derived toxin, is considered a potential weapon in biological warfare due to its high availability and ease of preparation. Pulmonary exposure to ricin results in the generation of an acute edematous inflammation followed by respiratory insufficiency and death. Passive immunization with polyclonal anti-ricin antibodies conferred protection against pulmonary ricinosis, however, at clinically-relevant time points for treatment, survival rates were limited. In this study, intranasal instillation of a lethal dose of ricin to mice, served as a lung challenge model for the evaluation and comparison of different therapeutic modalities against pulmonary ricinosis. We show that treatment with doxycycline resulted in a significant reduction of pro-inflammatory cytokines, markers of oxidative stress and capillary permeability in the lungs of the mice. Moreover, survival rates of mice intoxicated with ricin and treated 24 h later with anti-ricin antibody were significantly improved by co-administration of doxycycline. In contrast, co-administration of the steroid drug dexamethasone with anti-ricin antibodies did not increase survival rates when administered at late hours after intoxication, however dexamethasone did exert a positive effect on survival when applied in conjunction with the doxycycline treatment. These studies strongly suggest that combined therapy, comprised of neutralizing anti-ricin antibodies and an appropriate anti-inflammatory agent, can promote high-level protection against pulmonary ricinosis at clinically-relevant time points post-exposure.

2014-01-01·Colloids and Surfaces B: Biointerfaces2区 · 工程技术

The effect of anti-TGF-β2 antibody functionalized intraocular lens on lens epithelial cell migration and epithelial–mesenchymal transition

2区 · 工程技术

Article

作者: Teng, Wen-qi ; Yao, Ke ; Sun, Chuan-bin ; Cui, Jian-tao ; Huang, Xiao-jun

Migration and epithelial-mesenchymal transition (EMT) of lens epithelial cells (LECs) are main causes of central posterior capsule opacification after cataract extraction combined with intraocular lens (IOL) implantation. In this study, commercially available hydrophobic acrylic IOLs were first pretreated with atmospheric pressure glow discharge plasma to produce plenty of negatively charged chemical groups onto IOL surface, then polyethylenimine was deposited onto IOL surfaces as a precursor monolayer, and then anti-TGF-β2 (anti-T) antibody and poly-l-lysine were sequentially deposited onto IOL surface for four cycles followed by another upmost monolayer of anti-T antibody via layer-by-layer self-assembly technique. After the fabrication of anti-T antibody multilayers on IOL surface, the surface characteristics of the anti-T antibody functionalized IOL, as well as its effect on LECs adhesion, proliferation, migration and EMT were then tested in this study. Our results revealed that anti-T antibody multilayers could be successfully immobilized onto IOL surfaces by plasma pretreatment and layer-by-layer self-assembly technique, and could keep stable for at least 3 months on IOL surface. The anti-T antibody immobilized in the multilayers on IOL surfaces showed good immunological activity by its specific antigen-antibody interaction with exogenous TGF-β2. Anti-T antibody functionalized IOL surface was as smooth and flat as the untreated IOL surface. No difference in optical or physical properties was found between the anti-T antibody functionalized IOLs and the untreated IOLs. Compared with the untreated IOLs, the anti-T antibody functionalized IOL greatly inhibited LECs from migration and EMT, yet showed only transient inhibition to LECs adhesion and no inhibition to LECs proliferation. With these data, we demonstrate a simple, inexpensive, and feasible method to fabricate surface functionalized IOL for in situ capture and neutralization of TGF-β2 in the capsular bag, which might be a possible solution to preventing posterior capsule opacification after cataract surgery.

项与 Polyclonal anti-T-cell antibodies(Institute for Clinical and Experimental Medicine) 相关的新闻（医药）

2023-09-28

·BioSpace

Exagen Announces Acceptance of Multiple Abstracts at ACR 2023 Annual Meeting

SAN DIEGO, California, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the acceptance of five abstracts at the 2023 American College of Rheumatology’s (ACR) annual meeting, ACR Convergence 2023, being held November 10-15, 2023, at the San Diego Convention Center in San Diego, California. Below is the list of accepted abstracts, with links to each: Sunday, November 12, 2023 Poster Presentation | Presented by Doruk Erkan | Abstract #0099 Title: Cell-bound Complement Activation Products in Antiphospholipid Antibody-positive Patients Without Other Systemic Autoimmune Diseases Session Title: Poster Session A Session Time: 9:00 – 11:00am PT Poster Presentation | Presented by Jennifer Rogers | Abstract #0557 Title: Longitudinal Evaluation of Cell-bound Complement Activation Products in Patients with SLE Session Title: Poster Session A Session Time: 9:00 – 11:00am PT Poster Presentation | Presented by Andrew Concoff| Abstract #0575 Title: The Real-World Utility of a Lupus Activity Monitoring Panel in the United States Community Rheumatologist Practice Session Title: Poster Session A Session Time: 9:00 – 11:00am PT Poster Presentation | Presented by Andrew Concoff| Abstract #0576 Title: Enhancing Systemic Lupus Erythematosus Diagnosis: Comparative Performance Characteristics of TC4d and Anti-T-Cell Antibodies with Conventional Biomarkers Session Title: Poster Session A Session Time: 9:00 – 11:00am PT Tuesday, November 14, 2023 Poster Presentation | Presented by Vasileios Kyttaris| Abstract #2273 Title: Predicting SLE Disease Activity with Blood Biomarkers: A Step Towards Precision Medicine Session Title: Poster Session C Session Time: 9:00 – 11:00am PT About Exagen Inc. Exagen is a leading provider of autoimmune testing and its purpose as an organization is to provide clarity in autoimmune disease decision making with the goal of improving patients’ clinical outcomes. Exagen is located in San Diego County, California. For more information, please visit Exagen.com and follow @ExagenInc on X. Forward Looking Statements Exagen cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on Exagen’s current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding our clinical research and development team’s scientific abstracts for presentation at ACR Annual Conference and the potential to lead to increased adoption of any AVISE® test. The inclusion of forward-looking statements should not be regarded as a representation by Exagen that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Exagen’s business, including, without limitation: delays in reimbursement and coverage decisions from Medicare and third-party payors and in interactions with regulatory authorities, and delays in ongoing and planned clinical trials involving its tests; Exagen’s commercial success depends upon attaining and maintaining significant market acceptance of its testing products among rheumatologists, patients, third-party payors and others in the medical community; Exagen’s ability to successfully execute on its business strategies; third-party payors not providing coverage and adequate reimbursement for Exagen’s testing products, including Exagen’s ability to collect on funds due; Exagen’s ability to obtain and maintain intellectual property protection for its testing products; regulatory developments affecting Exagen’s business; and other risks described in Exagen’s prior press releases and Exagen’s filings with the Securities and Exchange Commission (“SEC”), including under the heading “Risk Factors” in Exagen’s Annual Report on Form 10-K for the year ended December 31, 2022 and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Exagen undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investor Relations Exagen Inc. Ryan Douglas rdouglas@exagen.com 760.560.1525 Company Exagen Inc. Kamal Adawi, Chief Financial Officer kadawi@exagen.com

100 项与 Polyclonal anti-T-cell antibodies(Institute for Clinical and Experimental Medicine) 相关的药物交易

登录后查看更多信息